Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA1 | P00915 | 15/20 | 0.52 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545698 | 0.97 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL545147 | 0.97 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL18917616 | 0.97 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL545689 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20583880 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1496640 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1831160 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1835423 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Silver SCHEMBL2906769 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Lithium Ion SCHEMBL21802717 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333240-B | Boron siloxane modified phenolic resin flame retardant, transparent flame-retardant polycarbonate composite material and preparation method thereof | 上海锦湖日丽塑料有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-4479476-A1 | FLAME-RETARDANT POLYCARBONATE COMPOSITION | Covestro Deutschland AG (DE) | 2024-12-25 | — | — | EP | claimed |
| CN-118696093-A | Flame retardant polycarbonate compositions | 科思创德国股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2023156339-A1 | FLAME-RETARDANT POLYCARBONATE COMPOSITION | COVESTRO DEUTSCHLAND AG (DE) | 2023-08-24 | — | — | WO | claimed |
| EP-4230697-A1 | HYDROLYSIS-RESISTANT POLYCARBONATE COMPOSITION | Covestro Deutschland AG (DE) | 2023-08-23 | — | — | EP | claimed |
| CN-112689661-B | Polycarbonate resin composition | 出光兴产株式会社 | 2023-07-07 | — | — | CN | claimed |
| CN-116333240-A | Boron siloxane modified phenolic resin flame retardant, transparent flame-retardant polycarbonate composite material and preparation method thereof | 上海锦湖日丽塑料有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-11469447-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2022-10-11 | — | — | US | claimed |
| US-20210194056-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING SULFONATE OR CARBOXYLATE SALT BASED COMPOUNDS | ENEVATE CORPORATION | 2021-06-24 | — | — | US | claimed |
| US-9570211-B2 | Transparent thermoplastic composition with improved electrical conductivity in the melt | COVESTRO LLC (US) | 2017-02-14 | — | — | US | claimed |
| EP-2318459-A2 | TRANSPARENT THERMOPLASTIC COMPOSITION WITH IMPROVED ELECTRICAL CONDUCTIVITY IN THE MELT | Bayer MaterialScience LLC (US) | 2011-05-11 | — | — | EP | claimed |
| WO-2010027417-A2 | TRANSPARENT THERMOPLASTIC COMPOSITION WITH IMPROVED ELECTRICAL CONDUCTIVITY IN THE MELT | BAYER MATERIALSCIENCE LLC (US) | 2010-03-11 | — | — | WO | claimed |
| US-20100051882-A1 | TRANSPARENT THERMOPLASTIC COMPOSITION WITH IMPROVED ELECTRICAL CONDUCTIVITY IN THE MELT | COVESTRO LLC | 2010-03-04 | — | — | US | claimed |
| WO-2026100197-A1 | POLYCARBONATE RESIN COMPOSITION | 三菱エンジニアリングプラスチックス株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20260015500-A1 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20260008920-A1 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | TEIJIN LIMITED (JP) | 2026-01-08 | — | — | US | disclosed |
| US-6472079-B2 | PRODUCT OF HYDROLYSIS AND CONDENSATION OF AN ORGANOSILICON COMPOUND; 1A OR 2A COMPOUND, ESPECIALLY CARBOXYLIC SALT; SOLVENT; EXCELLENT CRACKING RESISTANCE AFTER A PCT (PRESSURE COOKER TEST). | JSR CORPORATION (JP) | 2002-10-29 | — | — | US | disclosed |
| US-20020045693-A1 | Composition for film formation, method of film formation and silica-based film | JSR CORPORATION (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1191065-A1 | RECLAIMED RESIN COMPOSITION | Teijin Chemicals, Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1148105-A2 | Composition for film formation, method of film formation, and silica-based film | JSR Corporation (JP) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008920-A1 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | NOP2, CCT2, RPL8 | CA2 2384/4885CA1 1674/4885MMP1 4031/4885 |
| US-20260015500-A1 | POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE | CHERP, RER1, TAF1 | CA2 249/4885CA1 440/4885MMP1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.